Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 15/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.48 |
| ▸ | CDK1 | P06493 | 7/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14093058 | 0.99 | CDK2 (0.49) | CDK2KCNH2CDK1JAK2MAPK8 | |
| SCHEMBL14093057 | 0.92 | CDK2 (0.49) | CDK2KCNH2CDK1JAK2 | |
| Lithium Ion SCHEMBL4259673 | 0.90 | CDK2 (0.47) | CDK2KCNH2CDK1JAK2 | |
| SCHEMBL4260947 | 0.90 | CDK2 (0.47) | CDK2KCNH2CDK1JAK2MAPK8 | |
| SCHEMBL4243943 | 0.89 | CDK2 (0.53) | CDK2KCNH2CDK1JAK2 | |
| SCHEMBL4266036 | 0.89 | CDK2 (0.50) | CDK2KCNH2CDK1JAK2 | |
| SCHEMBL13879010 | 0.88 | CDK2 (0.54) | CDK2KCNH2CDK1JAK2 | |
| SCHEMBL4408272 | 0.88 | CDK2 (0.51) | CDK2KCNH2CDK1JAK2 | |
| SCHEMBL4259586 | 0.88 | CDK2 (0.48) | CDK2KCNH2CDK1JAK2 | |
| SCHEMBL4258937 | 0.88 | CDK2 (0.45) | CDK2KCNH2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2046782-A2 | IMIDAZOLYLPYRIMIDINE DERIVATIVES FOR TREATMENT OF DISEASES RELATED TO GLYCOGEN SYNTHASE KINASE (GSK3) | Astra Zeneca AB (SE) | 2009-04-15 | — | — | EP | claimed |
| WO-2008002244-A2 | IMIDAZOL-PYRIMIDINE DERIVATIVES FOR TREATMENT OF DISEASES RELATED TO GLYCOGEN SYNTHASE KINASE (GSK3) | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | claimed |
| EP-2046782-A2 | IMIDAZOLYLPYRIMIDINE DERIVATIVES FOR TREATMENT OF DISEASES RELATED TO GLYCOGEN SYNTHASE KINASE (GSK3) | Astra Zeneca AB (SE) | 2009-04-15 | — | — | EP | disclosed |
| US-20080188502-A1 | New Compounds I | ASTRAZENECA AB (SE) | 2008-08-07 | — | — | US | disclosed |
| WO-2008002244-A2 | IMIDAZOL-PYRIMIDINE DERIVATIVES FOR TREATMENT OF DISEASES RELATED TO GLYCOGEN SYNTHASE KINASE (GSK3) | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188502-A1 | New Compounds I | SLC10A1, REN, SLC5A1 | CDK2 3536/4885KCNH2 741/4885CDK1 2357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.